Health technology pioneer Ilkka Korhonen joins CardioSignal as Chief Technology Officer
August 13, 2024
Korhonen will lead the development of CardioSignal’s novel gyrocardiography technology to speed up its adoption across new emerging clinical applications, primarily in heart failure and aortic stenosis.
Korhonen has over 30 years’ experience in biosensors, algorithms and wearables in both international business and academia. His data science and algorithm expertise strengthens the core of CardioSignal’s clinical-grade technology, which utilizes the built-in motion sensors of smartphones to measure and analyze heart function.
“With remarkable experience in health technologies spanning over three decades, Ilkka is a rare find and the perfect fit as the new CTO of CardioSignal. Ilkka has been a startup founder and worked for some of the biggest technology companies in the world. He will play a crucial role in converting our successes from clinical studies into field-changing heart disease detection tools in primary and remote care,” says cardiologist Juuso Blomster, CEO and co-founder of CardioSignal.
In the course of his career, Korhonen has overseen the launch of several new technologies in digital health, from consumer health to medical devices. In addition to his vast product engineering experience, Korhonen has authored over 200 scientific publications, contributed to numerous clinical studies, and patented technologies and user-centric solutions in remote care for chronic conditions.
“CardioSignal is a fascinating company using a technology that powers consumer devices – mobile phones – to be used for medical grade detection of serious heart diseases. The potential of this technology is dramatic due to its accessibility to almost all citizens at a fraction of the cost compared to solutions that require dedicated hardware. This intersection between consumer and medical technology is perhaps the hottest spot for med tech today, and I am excited to join the CardioSignal team to further scale up the capabilities and reach of our products,” states Ilkka Korhonen.
Highlights from Korhonen’s career:
SW Engineering Manager, GE Healthcare (2023-2024)
Clinical Algorithm Lead, Meta (2022-2023)
CTO and VP Technologies, Firstbeat Technologies (2017-2022)
CTO, co-founder of PulseOn (2012-2017)
Professor, Tampere University of Technology (2011-2015), Adjunct Professor 2000-2011 and 2015-
Chief Research Scientist and various roles, VTT (1996-2010)
Further information:
Ilkka Korhonen, CTO, ilkka.korhonen@cardiosignal.com
Juulia Simonen, communications, juulia.simonen@cardiosignal.com, +358503059018
About CardioSignal
CardioSignal develops groundbreaking solutions for the detection of heart diseases using digital cardiac biomarkers. The CardioSignal technology utilizes the gyroscope and accelerometer motion sensors to non-invasively measure heart motion to determine cardiac health and function. Originally an academic spin-off, the company’s patented gyrocardiography technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior Ltd, an ISO 13485 and 27001 certified health technology company formed in 2017 with operations in Turku, Finland and Palo Alto, CA, USA.
